AfterRaise/Companies/Matchpoint Therapeutics

Matchpoint Therapeutics

Matchpoint Therapeutics is a biotechnology company advancing the discovery of precision covalent medicines. From its funding announcement.

$150M Series BRaised 3 days agoWatertown, USABiotech & PharmaUSA

In their own words

What Matchpoint Therapeutics says it is doing

Work here? Claim your company profile

Public signal Described in the funding announcement as "biotechnology company advancing the discovery of precision covalent medicines". Source

ProductResearch and development

Public signal Read from the company's own description of what the funding supports.

Why now

Where Matchpoint Therapeutics is today

Matchpoint Therapeutics announced a Series B round of $150M on 9 October 2026, led by Nextech Invest and Norwest.

Latest round
Series B
Amount
$150M
Announced
9 October 2026
Headquarters
Watertown, USA
Sector
Biotech & Pharma
Investors
Also participating
Invus, BB Biotech, T1D Fund, BOLD Longevity Growth
Relevant leadership
Not stated

Momentum AfterRaise intelligence

AfterRaise Score

80
High momentum
1 funding signal in the last 90 days
Funding recency
40/40
announced within the last 30 days
Round scale
22/25
round size relative to the market
Funding stage
18/20
Series B
Funding cadence
0/15
one funding event tracked this year
Arriving with the signals layer
  • Hiring momentum Open roles and hiring pace
  • Market expansion New offices and new countries
  • Leadership Executive appointments
  • Product activity Launches and releases

Since the raise

What has happened since

  • 9 October 2026
    $150M Series B
    Led by Nextech Invest and Norwest.

Public signal The timeline currently holds funding events, because those are the signals AfterRaise observes today. Hiring, leadership, expansion and product events join it with the signals layer.

What may happen next

What this raise could create

AfterRaise intelligenceNot a statement of fact

What may happen next

  • Product launches and new tiers
  • Product leadership hiring
  • Research programme expansion
  • Scientific team growth

Opportunities this could create

  • Clinical operations
  • Scientific hiring
  • Licensing and BD partnerships
  • Product leadership
  • Design partners

Based on the Biotech & Pharma sector, a Series B round and the priorities the company itself set out. Not a statement of fact.

Medium momentum3 connected signals
  • 9 October 2026$150M Series B announced
  • 9 October 2026Stated priority: product
  • 9 October 2026Stated priority: research and development

High momentum means several meaningful company changes have occurred in a short period. Signals here are funding events and the priorities the company stated; hiring, leadership and expansion detection join with the signals layer.

Open to

What Matchpoint Therapeutics is open to

Not yet specified

Matchpoint Therapeutics has not told AfterRaise which approaches it welcomes. Until it does, we do not assume. Offers to help are held and shown to the company, and the company decides whether to open a conversation.

Work here? Set your preferences

Opportunities

Ways to work with Matchpoint Therapeutics

No open opportunities listed

Jobs, projects, partnerships, advisory and supplier needs appear here once the company has claimed its page and published them, and any role we read from its own job board appears automatically.

Work here? Open the first one

Helpful contributors

People who have contributed here

Nobody yet

When someone offers help and the company says it was useful, they appear here. Reputation on AfterRaise is built from contributions the company confirmed, not from follower counts.

Do you work at Matchpoint Therapeutics?

Claim your company profile.

This page was created from publicly available information. A verified representative corrects the record, says what the company is building next and chooses which conversations it welcomes.

What we do not have yet: your website, the roles and projects you have open and who leads the team. Claiming the page is how you fill those in.

Someone else requesting access does not give them ownership. Every representative is verified by a person before access is granted.

Maintaining your own company profile is free. A founder, CEO or authorised senior colleague can represent the company.

Also moving

Other Biotech & Pharma companies

See the sector